What Is a Multi-Cancer Early Detection (MCED) Test?
A multi-cancer early detection test looks for signals from many cancers in one blood draw. It is a screening adjunct, not a diagnosis, and does not replace guideline screening.
Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 27, 2026.
A multi-cancer early detection (MCED) test is a single blood test that screens for molecular signals associated with several different cancers at once. It is meant to add coverage on top of the cancer screening you already do, such as mammography or colonoscopy. It is a screening tool, not a diagnosis. A result that finds no signal does not mean you are cancer-free, and a result that finds a signal is not a cancer diagnosis: it points to the need for a confirmatory workup ordered by a doctor. Read this way, an MCED test can help surface cancers that have no routine screening test at all.
What does an MCED test actually look for?
Most solid tumors shed fragments of DNA into the bloodstream. An MCED test uses next-generation sequencing to read those fragments and look for patterns that suggest cancer somewhere in the body. LucenceINSIGHT, the MCED test Mito offers, works from a single blood draw and combines three signals: circulating tumor DNA (ctDNA) mutations, cancer-associated viral DNA (for cancers linked to viruses such as Epstein-Barr virus and HPV), and a machine-learning model that predicts the likely tissue or tumor of origin. The idea is to move from “there is a signal” to “the signal most likely comes from here,” so a clinician has a starting point for follow-up.
One feature that sets LucenceINSIGHT apart from a fixed one-size panel is that the panel can be personalized. You and your doctor decide how wide to cast the net based on your age, family history, and personal risk, rather than everyone running the identical test.
Why would anyone screen for cancer this way?
Cancer is the second leading cause of death worldwide, according to the World Health Organization. The gap MCED tries to close is coverage. Routine, guideline-recommended screening exists for only a handful of cancers (breast, cervical, colorectal, lung in higher-risk smokers, and prostate by shared decision). Analyses derived from GLOBOCAN 2024 incidence and mortality data, set against the cancers the U.S. Preventive Services Task Force recommends screening for, indicate that over half of U.S. cancer deaths come from cancers with no recommended screening test. Many of those cancers are found only once symptoms appear.
Timing matters because stage at diagnosis drives outcomes. Zeng and colleagues reported in The Lancet (2021) that 52.8% of cancers were diagnosed at a late stage. Five-year survival is far higher when cancer is caught early, as the U.S. National Cancer Institute’s SEER program data show below.
Cancer | Late stage (III-IV) 5-yr survival | Early stage (I-II) 5-yr survival |
|---|---|---|
Pancreatic | 3.2% | 43.6% |
Liver | 3.5% | 37.6% |
Lung | 9.7% | 64.7% |
Colorectal | 16.2% | 91.5% |
Ovarian | 31.8% | 91.7% |
Breast | 32.6% | 99.9% |
Thyroid | 50.2% | 99.9% |
5-year relative survival by stage at diagnosis. Source: NIH NCI SEER.
One caution about older single-marker blood tests used for screening: they can raise a lot of false alarms. In a large screening trial, Croswell and colleagues found a cumulative false-positive rate of roughly 43% across 14 screening exams using standard methods (Annals of Family Medicine, 2009). That is a reason to treat any single positive signal, from any test, as a prompt for careful workup rather than a verdict.
How well does LucenceINSIGHT perform?
Lucence reports the following from its validation work, and the numbers should be read with their study populations attached. In a retrospective analysis of cancer patients across multiple stages, overall sensitivity was 80.9% (233 of 288 patients). Specificity was 99.0% in 313 self-declared healthy donors (310 correctly called negative). Tumor-localization accuracy was 87.7% overall (mean 84.9% across cancer types, range 33.3% to 100%), with a high-confidence prediction possible in about 62.4% of cases. Lucence’s brochure rounds this to roughly 88% accuracy in tumor localization. In a prospective real-world cohort of 264 asymptomatic individuals (2023) and a retrospective cohort of 601 samples (2024), Lucence reported 100% positive predictive value, with all three positive signals in the prospective cohort correlating with a newly diagnosed cancer. These are small cohorts, so read the figures as encouraging early evidence, not settled population performance.
Several limits belong next to those numbers. Sensitivity varies a lot by cancer type and by stage, and detection is generally easier at later stages than at Stage I. A cancer being “on the panel” does not mean it is equally detectable. A negative result does not mean you are cancer-free. And brain tumors are excluded, because they release little ctDNA into the blood. LucenceINSIGHT is a prescription-only laboratory-developed test performed in a CLIA/CAP-accredited lab. It is not FDA-cleared, and it does not assess inherited or germline cancer risk, so it is not a substitute for genetic counseling.
Who is an MCED test for?
Lucence positions LucenceINSIGHT for adults 40 and older, or for younger adults with elevated risk from family history, diet, or lifestyle. It is generally not a fit, subject to your doctor’s judgment, for people who are pregnant, in cancer remission for less than three years, or who have had surgery, an allogeneic bone-marrow transplant, or a blood transfusion within two weeks of the draw. No fasting is required, though a heavy meal within four hours of the draw is best avoided. Turnaround is about 18 working days.
Not sure whether MCED fits your situation? The Cancer Risk Profile quiz is a quick way to think through your personal risk before you talk to a clinician.
Core, Me, or 12: how wide should the net be?
LucenceINSIGHT comes in three panels that trade focus for breadth. Coverage figures below are conservative mortality-share estimates derived from GLOBOCAN 2024, using the brochure’s USPSTF-excluded framing.
Panel | Cancers covered | Share of U.S. cancer mortality |
|---|---|---|
Core | 6 (thyroid, breast, pancreatic, colorectal, lung, liver) | >50% |
Me | 9 (Core plus up to 3 chosen with your doctor from a curated list of 12) | 53-76% (varies by selection) |
12 | 12 (comprehensive, gender-specific panel) | ~78% |
Panel coverage of U.S. cancer mortality. Source: GLOBOCAN 2024 (conservative estimates, USPSTF-excluded framing).
There is no single right answer here. Breadth has value because tumor-of-origin prediction is imperfect and a wider net catches more. Focus has value because risk, detectability, and the usefulness of acting on a result all differ by cancer. LucenceINSIGHT Me is the panel built for personalization, letting you weigh your own risk against what is detectable and what you could actually do about it. LucenceINSIGHT 12 casts the widest net Mito offers.
Where Mito is different
Mito does not just resell a blood test. LucenceINSIGHT is ordered through Mito’s telehealth flow, and a positive or ambiguous signal lands inside Mito’s care model rather than as a lonely PDF. Your MCED result sits alongside your other Mito results, more than 60 biomarkers spanning heart, metabolic, liver, kidney, and hormone health, so a clinician reads the cancer signal in the context of your whole picture. Mito’s Concierge and 1:1 clinician consults help you decide what the next step should be, and membership is $9 per month with tests offered at Mito’s cost. For current LucenceINSIGHT pricing, see the panel pages; Mito does not quote a fixed test price here because it can change.
Frequently asked questions
Is an MCED test the same as a cancer diagnosis? No. It is a screening test. A signal means a doctor should order confirmatory testing, such as imaging or a biopsy, to find out whether cancer is actually present.
If my MCED result finds no signal, am I in the clear? No. A negative result lowers the probability of the cancers screened, but it does not rule cancer out, and sensitivity varies by cancer and stage. Keep up with your guideline-recommended screening.
Does an MCED test replace my mammogram or colonoscopy? No. It is designed to complement standard screening, not replace it. Guideline screening remains the foundation.
Does it tell me my inherited cancer risk? No. LucenceINSIGHT looks for signals of cancer that may already be present. It does not assess germline or inherited risk and is not a substitute for genetic counseling.
Which cancers can it not detect? Brain tumors are excluded because they release little ctDNA into the blood, and any cancer not on your chosen panel is not screened. “On the panel” also does not mean “equally detectable.”
Related reading
- How Ancestry, Genetics, and Aging Shape Your Cancer Risk
- Multi-Cancer Early Detection Test: A Complete Guide
- Building a Personalized Cancer Screening Plan After 40
- Galleri vs. LucenceINSIGHT: MCED Tests Compared
- Multi-Cancer Blood Test Cost and How to Get One
- CA-125 (Cancer Antigen 125)
Medical disclaimer
This article is for informational purposes only. It does not diagnose cancer, provide medical advice, or replace care from a qualified clinician. Multi-cancer early detection tests, including LucenceINSIGHT, are prescription-only laboratory-developed tests that are not FDA-cleared. They are screening adjuncts, not diagnostic tests, and do not replace guideline-recommended cancer screening. A result that finds no signal does not mean you are free of cancer, and a result that finds a signal requires confirmatory evaluation ordered by a doctor. Talk with a qualified clinician about whether testing is appropriate for you and how to interpret any result.
